SOURCE: CLX Medical, Inc.

August 18, 2008 10:44 ET

CLX Medical, Inc. Issues August 2008 Newsletter Highlighting Planned Acquisition of the ThyroTest® Rapid Screening Device

Newsletter Also Covers Additional Recent Announcements Regarding New Master Distributor for European Market and CEO Q&A

MURRIETA, CA--(Marketwire - August 18, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced the release of the company's August 2008 investor newsletter, which highlights the company's recent announcement of a letter of intent with ThyroTec, LLC to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease.

A PDF version of the August 2008 newsletter can be viewed on the company's corporate website at http://www.clxmedical.com/newsletters.php.

With the letter of intent announced, CLX will now proceed toward a definitive agreement for the acquisition of ThyroTest®, which would be positioned in a wholly owned subsidiary of CLX Medical. ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors' offices in the U.S., as well as in any non-waived laboratory.

In addition to the planned acquisition of ThyroTest®, the newsletter reviews agreement with LETI Laboratories, a Barcelona-based biopharmaceutical company that operates with exclusive distributors in countries across Europe, to serve as the sole importer of CLX's subsidiary products into the European market. As Master Distributor for CLX products, LETI Laboratories will provide product support and product packaging control; coordinate sales to other European distributors; distribute the company's products in Spain and Portugal; act as the registered EU representative for CE marked products; serve as the one point of entry for CLX products into Europe; and assist with the development and implementation of pricing structures.

In the place of a CEO Greeting, a CEO Question and Answer featuring Vera Leonard that was recently posted to the CLX Medical website has been included in the newsletter.

"The announcement of ThyroTest® as the targeted acquisition for CLX and the selection of LETI Laboratories to serve as the sole importer of CLX's subsidiary products into the European market are both milestone events for the company, and we are pleased to have the opportunity to review them in our investor newsletter," stated Ms. Leonard. "As important as these announcements are, we expect additional significant events to follow, and we hope that shareholders will continue to monitor the evolving story of CLX Medical."

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in Zonda, Inc. (www.zondaincusa.com), which has developed several rapid point of care tests for medical and non-medical markets, including a rapid test for Chlamydia. CLX recently announced a letter of intent to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX Medical is focused on the successful worldwide distribution of these and any additional products it may acquire or license.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications, Inc.
    A. Beyer
    951-677-8073
    Email Contact